Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients
Sandesh Madhukar Bharati1★, Nishith Singh2★ Corresponding author
- 1Department of Pharmacology, SMBT Institute of Medical Sciences and Research Centre, Dhamangaon, Nashik, India.
- 2Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India.
CORRESPONDENCE
Sandesh Madhukar Bharati
Department of Pharmacology, SMBT Institute of Medical Sciences and Research Centre, Dhamangaon, Nashik, India.
Received: 03-10-2015; Revised: 10-12-2015; Accepted: 03-01-2016.
Volume 7, Issue 2 · pp. 80–86 · PUBLISHED 2016 · DOI: 10.4103/0976-500X.184771
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Objective: To study the effects of losartan and atenolol on glucometabolic parameters in nondiabetic hypertensive patients. Materials and Methods: In a prospective, open‑label, parallel group study, nondiabetic patients with mild to moderate hypertension were randomized to either losartan (titrated from 50 to 100 mg/day, n = 20) or atenolol (titrated from 25 mg to 100 mg/day, n = 20) for period of 24 weeks. At baseline, 12 and 24 weeks fasting plasma glucose (FPG), fasting plasma insulin (FPI), homeostasis model assessment for insulin resistance (HOMA‑IR) apart from lipid parameters, mean systolic, and diastolic blood pressures levels were determined. Results: At the end of study, losartan significantly (P < 0.05) reduced FPG, FPI, and HOMA‑IR compared to atenolol and baseline. While atenolol increased the HOMA‑IR levels significantly compared to the baseline. Conclusions: Losartan improved the insulin sensitivity while atenolol worsened it. Losartan is better than atenolol for its effects on the glucose‑insulin metabolism.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Bharati, S. M., & Singh, N. (2016). Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients. Journal of Pharmacology and Pharmacotherapeutics, 7(2), 80–86. https://doi.org/10.4103/0976-500X.184771
